Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2002-05-16
2004-11-23
Jones, Dwayne (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S232200
Reexamination Certificate
active
06821970
ABSTRACT:
FIELD OF THE INVENTION
The present invention provides oxazinocarbazole derivatives having a ring connecting position 8 (C-8) and position 9 (N-9), and more specifically, provides compounds of formula (I) described herein below. These compounds are 5-HT ligands, and are useful for treating diseases wherein modulation of 5-HT activity is desired.
BACKGROUND OF THE INVENTION
Many diseases of the central nervous system are influenced by the adrenergic, the dopaminergic, and the serotonergic neurotransmitter systems. For example, serotonin has been implicated in a number of diseases and conditions which originate in the central nervous system. These include diseases and conditions related to sleeping, eating, perceiving pain, controlling body temperature, controlling blood pressure, depression, anxiety, schizophrenia, and other bodily states. R. W. Fuller, Biology of Serotonergic Transmission, 221 (1982); D. J. Boullin, Serotonin in Mental Abnormalities 1:316 (1978); J. Barchas, et al., Serotonin and Behavior, (1973). Serotonin also plays an important role in peripheral systems, such as the gastrointestinal system, where it has been found to mediate a variety of contractile, secretory, and electrophysiologic effects.
As a result of the broad distribution of serotonin within the body, there is a tremendous interest in drugs that affect serotonergic systems. In particular, receptor-specific agonists and antagonists are of interest for the treatment of a wide range of disorders, including anxiety, depression, hypertension, migraine, obesity, compulsive disorders, schizophrenia, autism, neurodegenerative disorders (e.g. Alzheimer's disease, Parkinsonism, and Huntington's chorea), and chemotherapy-induced vomiting. M. D. Gershon, et al., The Peripheral Actions of 5-Hydroxytryptamine, 246 (1989); P. R. Saxena, et al., Journal of Cardiovascular Pharmacology, 15:Supplement 7 (1990).
The major classes of serotonin receptors (5-HT
1-7
) contain fourteen to eighteen separate receptors that have been formally classified. See Glennon, et al.,
Neuroscience and Behavioral Reviews,
1990, 14, 35; and D. Hoyer, et al.
Pharmacol. Rev.
1994, 46, 157-203. Recently discovered information regarding subtype identity, distribution, structure, and function suggests that it is possible to identify novel, subtype specific agents, having improved therapeutic profiles (e.g. fewer side effects).
For example, The 5-HT6 receptor was identified in 1993 (Monsma et al. Mol. Pharmacol. 1993, 43, 320-327 and Ruat, M. et al.
Biochem. Biophys. Res. Com.
1993, 193, 269-276). Several antidepressants and atypical antipsychotics bind to the 5-HT6 receptor with high affinity and this binding may be a factor in their profile of activities (Roth et al.
J. Pharm. Exp. Therapeut.
1994, 268, 1403-1410; Sleight et al.
Exp. Opin. Ther. Patents
1998, 8, 1217-1224; Bourson et al.
Brit. J. Pharm.
1998, 125, 1562-1566; Boess et al.
Mol. Pharnacol.
1998, 54, 577-583; Sleight et al.
Brit. J. Pharmacol.
1998, 124, 556-562). In addition, the 5-HT6 receptor has been linked to generalized stress and anxiety states (Yoshioka et al.
Life Sciences
1998, 17/18, 1473-1477). Together these studies and observations suggest that compounds that antagonize the 5-HT
6
receptor will be useful in treating disorders of the central nervous system.
Compounds of the present invention are 5-HT ligands (e.g. receptor-specific agonists or antagonists). Thus they are useful for treating diseases wherein modulation of 5-HT activity is desired. Specifically, the compounds of this invention are useful in the treatment of psychosis, paraphrenia, psychotic depression, mania, schizophrenia, schizophreniform disorders, anxiety, migraine headache, drug addiction, convulsive disorders, personality disorders, post-traumatic stress syndrome, alcoholism, panic attacks, obsessive-compulsive disorders, and sleep disorders. The compounds of this invention are also useful to treat psychotic, affective, vegetative, and psychomotor symptoms of schizophrenia and the extrapyramidal motor side effects of other antipsychotic drugs. This last action will allow higher doses of antipsychotics to be used and thus greater antipsychotic efficacy to be obtained as a result of a reduction in side effects. The compounds of this invention are also useful in the modulation of eating behavior and thus are useful in treating excess weight and associated morbidity and mortality.
INFORMATION DISCLOSURE
International Publication No. WO97/45427 discloses pyridocarbazole derivatives having a highly selective cyclic GMP-phosphodiesterease inhibitory effect.
International Publication No. WO95/11245 discloses tetracyclic indole derivatives which have a selective antagonism against intestinal 5-HT3 receptors and are useful for preventing or treating digestive tract disorders such as irritable bowel syndrome and diarrhea.
Abstracts of SU-256776-S, SU-252342-S and SU-255278-S disclose 1,2-dihydropyrazino carbazoles useful as intermediates in the synthesis of biologically active compounds.
European Patent Application EP 377238 discloses annelated indolo [3,2-c] lactam derivatives having an antagonistic activity on 5-HT receptors. The compounds can be used for the treatment gastrointestinal system disorders, central nervous system disorders, cardiovascular disorders, respiratory system disorders, and for alleviating or preventing withdrawal symptoms which are induced by abuse of drugs.
European Patent Application EP 344015 discloses tetracyclic ketones useful in the treatment of psychotic disorders, anxiety, nausea, and vomiting in which a cyclohexanone ring system is fused to an indole system.
European Patent Application EP 297651 discloses tetracyclic ketones useful as antagonists of serotonin receptors in which a cyclohexanone ring system is attached to an indole system.
SUMMARY OF THE INVENTION
The present invention provides a compound of formula I
or a pharmaceutically acceptable salt thereof wherein
R
1
is
(a) H,
(b) halo, or
(c) C
1-6
alkyl;
R
2
is
(a) H,
(b) halo,
(c) —OH,
(d) —CN,
(e) —CF
3
,
(f) —O(C
1-6
)alkyl,
(g) C
1-6
alkyl,
(h) C
3-6
cycloalkyl,
(i) —NR
5
R
6
,
(j) —CONR
5
R
6
,
(k) —SO
2
NR
5
R
6
,
(l) —COOR
7
, or
(m) phenyl, optionally substituted with halo, OH, O(C
1-4
) alkyl, or C
1-6
alkyl;
R
3
is
(a) —(CH
2
)
m
—NR
8
R
9
wherein the —(CH
2
)
m
—chain may be substituted with one or two C
1-6
alkyl or C
3-6
cycloalkyl;
R
4
is
(a) aryl, or
(b) heteroaryl;
aryl is phenyl or naphthyl, optionally substituted with one or more R
10
;
hetetoaryl is a radical of a five- or six-membered monocyclic aromatic ring having one or two heteroatoms each selected from the group consisting of oxygen, sulfur, and N(X), or a radical of a nine- or ten-membered ortho-fused bicyclic aromatic ring having one, two or three heteroatoms each selected from the group consisting of oxygen, sulfur, and N(X); wherein X is absent, H or C
1-4
alkyl; wherein carbon atoms of heteroaryl may be substituted with one or more R
10
;
R
5
and R
6
is independently
(a) H,
(b) C
1-6
alkyl, or
(c) C
3-6
cycloalkyl;
R
7
is
(a) C
1-6
alkyl, or
(b) (C
1-3
alkyl)-phenyl wherein phenyl may be substituted with R
10
;
R
8
and R
9
is independently
(a) H,
(b) C
1-6
alkyl,
(c) C
3-6
cycloalkyl,
(a) C
2-4
alkyl substituted with —OH, —O(C
1-4
alkyl), —O(C
1-4
alkyl)—NR
11
R
12
, or —CO
2
R
5
,
(e) —CHO, with the proviso that only one of the R
8
and R
9
is CHO, the other one is hydrogen,
(f) —(CH
2
)
m
—phenyl wherein the phenyl may be substituted with halo, or
(g) R
8
and R
9
taken together with the nitrogen to which they are attached form a five-, six-, or seven-membered heterocyclic ring wherein the heterocyclic ring optionally has one to two additional heteroatoms selected from the group consisting of oxygen, sulfur and N(Y) and wherein the carbon atoms of the heterocyclic ring is optionally substituted with one or two R
13
;
Y is absent or R
14
;
R
10
is
(a) halo,
(b) —OH,
(c) —CN,
(d) —CF
3
,
(e) —O(C
1-6
)alkyl,
(f) C
1-6
alkyl,
(g) C
3-6
cycloalkyl,
(h) —NR
5
R
6
,
(i)
Hosley Mary J.
Jones Dwayne
Pharmacia & Upjohn Company
Yang Lucy X.
LandOfFree
Oxazinocarbazoles for the treatment of CNS diseases does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Oxazinocarbazoles for the treatment of CNS diseases, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Oxazinocarbazoles for the treatment of CNS diseases will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3353235